0633 GMT - Raffles Medical Group stands to benefit from medical tourism gradually returning to Singapore as the country reopens its borders, DBS Research says. Covid-19-related services like vaccinations are expected to taper, but the company remains a key provider of polymerase-chain-reaction tests at Singapore's Changi Airport and will likely benefit from pent-up travel demand, DBS adds. It expects Raffles Medical to post record earnings in 2022-23 and keeps a buy rating on the stock while raising the target price to S$1.81 from S$1.48. Shares rise 2.0% to S$1.53. (yongchang.chin@wsj.com)
Raffles Medical Set to Gain as Singapore's Medical Tourism Recovers -- Market Talk
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated